Tag: myeloma treatment
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell maturation (BCMA)-directed CD3 T-cell engager. The therapeutic armamentarium for myeloma now includes alkylating agents, corticosteroids, deacetylase inhibitors,…
Covid-19 Vaccines – What Multiple Myeloma Patients Should Know?
Multiple myeloma patients are often immunosuppressed for months following treatments such as maintenance therapies, immunosuppressive drugs, hematopoietic cell transplant (HCT) and CAR-T therapies. They are at higher risk for serious complications from the SARS-CoV-2 virus leading to hospitalizations and ICU…
Melflufen for Myeloma: A Deep Dive
The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended for use as a first choice for patients with multiple myeloma whose disease is refractory to at…
ASH 2020 Updates: CAR T Cell Therapies in Multiple Myeloma
We kickstart the new year with a discussion on CAR T cells in myeloma treatment with a focus on the CT053, a CAR T-cell therapy targeting the BCMA protein and granted orphan drug status by the U.S. Food and Drug…